Palbociclib (monohydrochloride)
Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma[1][3][4].
Product Specifications
CAS Number
[827022-32-2]
Product Name Alternative
PD 0332991 (monohydrochloride)
UNSPSC
12352005
Hazard Statement
H341, H361, H373, H411
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/palbociclib-monohydrochloride.html
Purity
99.98
Solubility
DMSO : 4.63 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C(C(C)=O)=C(C)C2=CN=C(NC3=NC=C(N4CCNCC4)C=C3)N=C2N1C5CCCC5.Cl
Molecular Formula
C24H30ClN7O2
Molecular Weight
483.99
Precautions
H341, H361, H373, H411
References & Citations
[1]Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3 (11) :1427-38. |[2]Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548 (7668) :471-475. |[3]Richard S Finn, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11 (5) :R77. |[4]Bollard J, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017 Jul;66 (7) :1286-1296.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CDK4; CDK6
Citation 01
BioRxiv. 2023 Mar 15.|bioRxiv. 2025 Nov 3:2025.11.02.685764.|bioRxiv. 2025 Sep 15.|Cancer Res. 2022 Jun 6;82 (11) :2110-2123.|Cell Rep. 2022 Mar 1;38 (9) :110448.|Cell Rep. 2023 Mar 30;42 (4) :112314.|Ecotoxicol Environ Saf. 2020 Dec 1;205:111146.|EMBO Mol Med. 2025 Aug 29.|Eur J Cancer. 2018 Oct:102:10-22.|Immunity. 2025 Apr 8;58 (4) :811-825.e7.|J Pathol. 2023 Jun;260 (2) :203-221.|J Transl Med. 2023 Feb 10;21 (1) :110.|Mol Cancer Res. 2018 Mar;16 (3) :361-377. |Mol Cell. 2020 Jun 18;78 (6) :1096-1113.e8. |Mol Cell. 2023 Nov 16;83 (22) :4062-4077.e5.|Mol Oncol. 2017 Aug;11 (8) :1035-1049.|Nature. 2017 Jun 15;546 (7658) :426-430.|Sci Adv. 2025 Aug 15;11 (33) :eadu2906.|Sci Data. 2024 Sep 19;11 (1) :1024.|University College Dublin. School of Biology and Environmental Science.|Acta Biomater. 2022 Sep 15:150:211-220.|Adv Sci (Weinh) . 2024 Aug 13:e2400666.|Am J Transl Res. 2019 Sep 15;11 (9) :6055-6065.|Biochem Biophys Res Commun. 2023 Apr 2:650:96-102.|Biochem Biophys Res Commun. 2025 Jun 18:777:152228.|Biochem Pharmacol. 2017 Jan 15:124:29-42.|Biochim Biophys Acta. 2017 Nov 20;1865 (2) :354-363.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2025 Aug:189:118340.|Biomolecules. 2025 Jun 16;15 (6) :873.|bioRxiv. 2023 Nov 23.|bioRxiv. 2023 Sep 18:2023.09.18.558307.|bioRxiv. 2024 Dec 5:2024.12.05.627000.|bioRxiv. 2024 July 05.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2024 Nov 4:2024.10.08.617155.|bioRxiv. 2025 Aug 30.|bioRxiv. 2025 August 24.|bioRxiv. 2025 March 06.|bioRxiv. 2025 May 10.|bioRxiv. 2025 Nov 4:2025.11.03.686258.|Br J Cancer. 2021 Jan;124 (1) :191-206.|Br J Cancer. 2022 Jun;126 (11) :1616-1626.|Breast Cancer Res. 2024 Jun 7;26 (1) :95.|Cancer Cell Int. 2024 Dec 27;24 (1) :433.|Cancer Cell. 2017 Apr 10;31 (4) :576-590.e8. |Cancer Cell. 2024 Aug 27:S1535-6108 (24) 00305-2.|Cancer Cell. 2024 Jul 8;42 (7) :1286-1300.e8.|Cancer Discov. 2024 Sep 13:OF1-OF20.|Cancer Lett. 2024 May 28:216996.|Cancer Res. 2019 Oct 15;79 (20) :5245-5259.|Cancer Res. 2021 Jan 1;81 (1) :187-198.|Cancer Res. 2023 Oct 2;83 (19) :3237-3251.|Cancer Res. 2024 Jan 2;84 (1) :17-25.|Cancers (Basel) . 2021 Mar 24;13 (7) :1494.|Cancers (Basel) . 2023 Mar 22;15 (6) :1908.|Cancers (Basel) . 2024 Aug 7;16 (16) :2785.|Cancers. 2020 Jun 16;12 (6) :1596.|Cell Biochem Biophys. 2025 Mar;83 (1) :1113-1137.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Cell Chem Biol. 2019 Aug 15;26 (8) :1067-1080.e8. |Cell Death Differ. 2020 Jun;27 (6) :1981-1997.|Cell Death Differ. 2022 Jul;29 (7) :1379-1394.|Cell Death Dis. 2020 Apr 6;11 (4) :219.|Cell Death Dis. 2020 Sep 15;11 (9) :760.|Cell Death Dis. 2022 Apr 2;13 (4) :295.|Cell Death Discov. 2024 Oct 26;10 (1) :453.|Cell Mol Gastroenterol Hepatol. 2022;14 (4) :769-788.|Cell Prolif. 2023 Jan;56 (1) :e13337.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep. 2022 Aug 16;40 (7) :111194.|Cell Rep. 2022 Nov 29;41 (9) :111716.|Cell Signal. 2025 Jul:131:111709.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell Syst. 2019 Jul 24;9 (1) :35-48.e5. |Cell Rep. 2020 Apr 14;31 (2) :107514.|Cells. 2023 Dec 30;13 (1) :81.|Clin Cancer Res. 2021 Apr 1;27 (7) :1855-1863.|Clin Cancer Res. 2024 Sep 13;30 (18) :4179-4189.|Clin Cancer Res. 2025 May 1;31 (9) :1667-1675.|Commun Biol. 2025 May 30;8 (1) :829.|Department of Biochemistry. 2020 Oct.|Dev Cell. 2023 Oct 9;58 (19) :1967-1982.e8.|Development. 2023 May 1;150 (9) :dev200903.|Discov Oncol. 2025 May 19;16 (1) :814.|EBioMedicine. 2019 May:43:171-179.|EBioMedicine. 2019 May:43:225-237.|EBioMedicine. 2024 Jul.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|EMBO J. 2021 Jun 1;40 (11) :e99692.|EMBO J. 2024 Nov;43 (22) :5381-5420.|EMBO J. 2024 Oct;43 (19) :4406-4436.|EMBO Rep. 2022 Jun 7;23 (6) :e53932.|Endocrinology. 2023 Aug 28;164 (10) :bqad135.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Front Cell Dev Biol. 2020 Aug 31;8:843.|Front Oncol. 2022 Apr 8;12:819003.|Future Med Chem. 2019 Feb;11 (3) :165-177.|GEN Biotechnol. 2025 Apr 17.|Harvard Medical School LINCS LIBRARY|Inflamm Res. 2023 Jun;72 (6) :1147-1160.|Int J Biol Sci. 2019 Jan 1;15 (3) :522-532. |Int J Biol Sci. 2021 Jan 31;17 (3) :728-741.|Int J Biol Sci. 2024 Sep 16;20 (12) :4978-4998.|Int J Mol Med. 2025 Nov;56 (5) :167.|Int J Mol Sci. 2019 Mar 5;20 (5) . pii: E1125. |Int J Mol Sci. 2021 Mar 25;22 (7) :3367.|Int J Mol Sci. 2023 Mar 12;24 (6) :5408.|iScience. 2022 Sep 6;25 (10) :105081.|J Biol Chem. 2023 Dec;299 (12) :105407.|J Biol Chem. 2023 Jun;299 (6) :104786.|J Biol Chem. 2024 Dec 10:108070.|J Bone Oncol. 2021 Sep 20:30:100391.|J Cell Mol Med. 2021 Mar;25 (6) :3124-3135.|J Cell Physiol. 2025 Nov;240 (11) :e70113.|J Exp Clin Cancer Res. 2018 Sep 20;37 (1) :233.|J Med Chem. 2021 Aug 12;64 (15) :10981-10996.|J Med Chem. 2021 Nov 11;64 (21) :15702-15715.|J Oncol. 2022 Sep 27:2022:2260625.|J Transl Med. 2019 Aug 20;17 (1) :276.|JCI Insight. 2021 Apr 8;6 (7) :e139497.|JHEP Rep. 2024 Oct 5;7 (1) :101230.|Leuk Res. 2022 Sep:120:106920.|Life Sci. 2023 Jun 1:322:121652.|Mar Drugs. 2020 Sep 27;18 (10) :494.|MedComm (2020) . 2022 Jun 10;3 (3) :e136.|Mol Cancer Ther. 2025 Jul 2.|Mol Cell. 2017 Oct 19;68 (2) :336-349.e6.|Mol Cell. 2023 Oct 5;83 (19) :3558-3573.e7.|Mol Oncol. 2023 Dec;17 (12) :2507-2525.|Mol Ther-Nucl Acids. 2023 Mar.|Molecules. 2023 May 27;28 (11) :4380.|Nat Commun. 2018 Oct 9;9 (1) :4180. |Nat Commun. 2020 Aug 13;11 (1) :4053.|Nat Commun. 2021 Jul 22;12 (1) :4457.|Nat Commun. 2021 Nov 16;12 (1) :6607.|Nat Commun. 2023 Jul 14;14 (1) :4221.|Nat Commun. 2024 Feb 16;15 (1) :1442.|Nat Commun. 2025 Feb 25;16 (1) :1774.|Nat Commun. 2025 Jul 1;16 (1) :5959.|Nat Commun. 2019 Nov 7;10 (1) :5076. |Nat Methods. 2022 Mar;19 (3) :331-340.|Nature Cancer. 2021 Jan;2 (1) :34-48.|Nature. 2017 Aug 24;548 (7668) :471-475. |Nature. 2020 Jul;583 (7817) :620-624.|Neoplasia. 2018 Mar 28;20 (5) :478-488. |Neoplasia. 2024 Aug 14:57:101039.|Neuron. 2025 May 21;113 (10) :1614-1628.e11.|NPJ Breast Cancer. 2025 Nov 12;11 (1) :125.|NPJ Precis Oncol. 2021 Mar 19;5 (1) :20.|Oncogene. 2022 Jul;41 (27) :3524-3538.|Patent. US11761044.|Patent. US20200108066A1|Patent. US20230149350A1.|Patent. US20240307414A1.|Phytomedicine. 2024 May 28:131:155775.|PLoS One. 2024 Aug 8;19 (8) :e0306545.|PLoS One. 2024 Jul 11;19 (7) :e0305612.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|PRACTICAL ONCOLOGY JOURNAL. 2018, 32 (3) : 193-197.|Practical Oncology Journal. 2018,32 (03) :193-197.|Res Sq. 2024 Jun 04.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 9.|Research Square Preprint. 2023 Nov 30.|Research Square Preprint. 2024 Nov 06.|Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Rep. 2023 Jan 31;13 (1) :1711.|Sci Rep. 2024 May 8;14 (1) :10582.|Sci Rep. 2025 Nov 29.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|SSRN. 2022 Nov 21.|SSRN. 2025 Aug 14.|SSRN. 2025 Oct 15.|Technische Universitat Darmstadt. 2025 May 8.|Technischen Universität Dresden . 11 June 2021.|Technischen Universität München. Fakultät für Medizin.|Texas Southern University. 2024 July 02.|Transl Oncol. 2025 Jan 3:52:102264.|Trends Biotechnol. 2025 Jul;43 (7) :1743-1764.|University of Coruña. Facultade de Ciencias da Saúde. 2022 Oct.|University of Coruña. Facultade de Ciencias. 2022 Jan.|University of Dundee. 2023 Jan.|University of Jena. 2025.|University of Texas. UTHealth Graduate School of Biomedical Sciences. 2021 Sep.|World J Surg Surgical Res. 2023 Jun 28.|Aging Cell. 2022 Apr;21 (4) :e13580.|bioRxiv. 2023 Mar 30.|bioRxiv. 2023 Sep 16:2023.09.15.554413.|Cancer Res. 2023 Oct 2;83 (19) :3264-3283.|Cell Rep. 2019 Mar 5;26 (10) :2667-2680.e7.|EMBO J. 2022 Mar 15;41 (6) :e109760.|J Biol Chem. 2025 Jan 16:108196.|J Virol. 2023 Jun 29;97 (6) :e0037023.|Laurentian University. Chemical Sciences. 2021 Oct.|Mol Cancer. 2022 Aug 30;21 (1) :171.|Mol Cancer. 2024 Jun 3;23 (1) :118.|Nat Commun. 2021 Aug 25;12 (1) :5112.|Nat Commun. 2022 Aug 10;13 (1) :4689.|Nature. 2020 Dec;588 (7836) :169-173.|NPJ Breast Cancer. 2021 Jan 4;7 (1) :2.|NPJ Precis Oncol. 2025 Jul 25;9 (1) :260.|Sci Rep. 2025 Jan 18;15 (1) :2415.|Syddansk Universitet. 2023 May 22.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|Cell Chem Biol. 2025 Apr 17;32 (4) :556-569.e24.|J Clin Invest. 2025 Aug 12:e188839.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
302598-ML650 100 µL
NFE4 (Transcription Factor NF-E4, NFE4) (MaxLight 650) discontinued
Ask
View Details 
